NVAX (Novavax Pharma) Prakiraan rega marang bathi

Novavax, Inc. (NVAX) bet on developing combined influenza and COVID vaccines is reflected in the dynamics of the company's forward P/E ratio, where the value of 0.00 expresses the metric level. However, the post-pandemic revenue collapse has eliminated cash flow predictability. The business currently relies critically on the commercialization of new product lines and aggressive cost restructuring for survival.

NVAX - Kapitalisasi marang proyeksi bathi Novavax ing rentang 04.07.2022 - 14.11.2026

Rincian analitis perusahaan Novavax, Inc.

- rega saiki lan proyeksi nilai saham:

Kutipan saham Novavax Corp|NVAX - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Biji pasar Novavax Pharma|NVAX - Nilai Total Perusahaan

- statistik nilai buku emiten:

Nilai Buku saben Saham Novavax|NVAX - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku novavax.com|NVAX - Nilai Agregat Aset

- statistik kawajiban utang lan likuiditas:

Rasio Total Utang marang Ekuitas Novavax, Inc.|NVAX - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Novavax Inc|NVAX - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Novavax, Inc.|NVAX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Novavax|Indikator likuiditas cepet novavax.com

- statistik bathi lan rasio pasar:

NVAX - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Novavax, Inc.|NVAX - Pangali P/E|Prakiraan rega marang bathi Novavax, Inc.|NVAX - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Novavax Corp|NVAX - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Novavax|NVAX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan novavax.com|NVAX - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Novavax, Inc.

- data pendapatan lan penerimaan dodolan:

NVAX - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan Novavax, Inc.|NVAX - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S Novavax

Analisis dhasar perusahaan:NVAX Novavax, Inc.

Novavax, Inc. (NVAX) maintains a strong position due to streamlined global logistics and seamless drug distribution. The company's forward P/E ratio compares current market value with expected net income for the coming year. This indicator allows investors to assess the extent of the premium paid for future earnings. By analyzing this chart, one can determine the optimal entry point into the asset. A low multiple confirms the fundamental stability of the business.

Karo sapa Novavax, Inc. saingan

Prakiraan rega marang bathi GILD (Gilead Sciences Inc)|CDTX (Cidara Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|CureVac N.V. - Prakiraan rega marang bathi|Valneva SE - Rega marang bathi mangsa ngarep|VIR - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi SIGA Technologies Inc SIGA|EBS (Emergent BioSolutions Inc) - Prakiraan rega marang bathi|Atea Pharmaceuticals - Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi IVVD|Pangali Forward P/E enanta.com|Pangali Forward P/E INO|Kapitalisasi marang proyeksi bathi HilleVax|Rega marang bathi mangsa ngarep Kalaris Therapeutics Inc. KLRS|DYAI: Rasio rega marang bathi mangsa ngarep|NanoViricides, Inc. - Pangali Forward P/E|TLPH - Pangali Forward P/E|COCP: Pangali Forward P/E|Traws Pharma, Inc. (TRAW) - Pangali Forward P/E|Prakiraan rega marang bathi DWTX|Rega marang bathi mangsa ngarep QLGN|Prakiraan rega marang bathi ALVR (AlloVir)|Rega marang bathi mangsa ngarep VBIV (VBI Vaccines)|Rega marang bathi mangsa ngarep virios.com VIRI|Rasio kapitalisasi marang bathi mangsa ngarep VXRT (vaxart.com)